myopic maculopathy
Conditions
Interventions
Red light treatment is performed for 2 months us ing the research device Eyerising Myopia Manage ment Device. Red light therapy is phototherapy us ing low power red light at 650 nm. Subjects will be t
Phototherapies, Myopia prevention therapy
Sponsors
Ohno Kyoko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Provision of consent. (2) Age. 18 years or older. (3) Patients whose color fundus photographs show either tessellated fundus or diffuse choroidal atrophy in both eyes. The presence or absence of a posterior staphyloma is not required. (4) High myopia. sphere is less than -6.00D. (5) Patients with a central foveal choroidal thickness(SFCT) of between 50 micrometres and 120 micrometres in both eyes. (6) Willing and able to participate in all required of the study.
Exclusion criteria
Exclusion criteria: (1) Secondary myopia, such as a history of retinopathy of prematurity or neonatal problems, o r syndromic myopia with a known genetic disease or connective tissue disorders, such as Stickler or Marfan syndrome. (2) Patients with retinitis pigmentosa-related diseases or other retinal hereditary diseases in the family. (3) Patients with night blindness. (4) Strabismus and binocular vision abnormalities in either eye. (5) Previous any intraocular surgery affecting refractive status. (6) Patients who have received low-dose atropine eye drops, orthokeratology, or progressive multifocal frame myopia progression control treatment in the past year. (7) Patients with myopic maculopathy plus lesions (myopic choroidal neovascularization, Fuchs spots, Lc). (8) Patients with systemic diseases (cardiac, respiratory, etc.). (9) Other reasons, including but not limited to ocular or other systemic abnormalities, that the physician may consider inappropriate for enrolment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of choroidal thickening greater than 5 percentage compared to baseline at 2-month follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Incidence rate of choroidal thickening greater than 10 percentage compared to baseline at 2-month follow-up. (2) Changes of choriocapillaris flow deficit, choroidal vascularity index, choroidal thickness assessed by ultrawide-field/widefield OCT scan at 1-, 3-, 6- and 12-month follow-up visits compared with those at baseline. (3) Best corrected visual acuity, OCT structural changes on neurosensory layer, RPE and choroidal layer, selfreported AE. (4) Changes in AL and other biometric parameters at 2-month follow-up. (5) Change in SER at 2-month follow-up. (6) Change of META-PM grading at 2-month follow-up. (7) Report of adverse events by questionnaire and interview/examination at the time of visit. | — |
Contacts
Public ContactTae Igarashi
Institute of Science Tokyo Hospital
Outcome results
None listed